JP2008515870A - 経鼻投与用組成物 - Google Patents
経鼻投与用組成物 Download PDFInfo
- Publication number
- JP2008515870A JP2008515870A JP2007535251A JP2007535251A JP2008515870A JP 2008515870 A JP2008515870 A JP 2008515870A JP 2007535251 A JP2007535251 A JP 2007535251A JP 2007535251 A JP2007535251 A JP 2007535251A JP 2008515870 A JP2008515870 A JP 2008515870A
- Authority
- JP
- Japan
- Prior art keywords
- dry powder
- powder composition
- nasal
- agent
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 239000003814 drug Substances 0.000 claims abstract description 66
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 51
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 45
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 45
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 45
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000000843 powder Substances 0.000 claims abstract description 36
- 239000001913 cellulose Substances 0.000 claims abstract description 8
- 239000003061 homeopathic agent Substances 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 230000011664 signaling Effects 0.000 claims description 16
- 239000013543 active substance Substances 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 5
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 5
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 5
- -1 iridoid Natural products 0.000 claims description 5
- 235000019814 powdered cellulose Nutrition 0.000 claims description 5
- 229920003124 powdered cellulose Polymers 0.000 claims description 5
- 238000013268 sustained release Methods 0.000 claims description 5
- 239000012730 sustained-release form Substances 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 241000207199 Citrus Species 0.000 claims description 4
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims description 4
- 244000131360 Morinda citrifolia Species 0.000 claims description 4
- 235000016698 Nigella sativa Nutrition 0.000 claims description 4
- 244000090896 Nigella sativa Species 0.000 claims description 4
- 235000011941 Tilia x europaea Nutrition 0.000 claims description 4
- 240000006909 Tilia x europaea Species 0.000 claims description 4
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 claims description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
- 235000020971 citrus fruits Nutrition 0.000 claims description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 4
- 239000004571 lime Substances 0.000 claims description 4
- 235000017524 noni Nutrition 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 3
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 3
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 3
- 244000273928 Zingiber officinale Species 0.000 claims description 3
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 235000008397 ginger Nutrition 0.000 claims description 3
- 229940041616 menthol Drugs 0.000 claims description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- 240000000073 Achillea millefolium Species 0.000 claims description 2
- 235000007754 Achillea millefolium Nutrition 0.000 claims description 2
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims description 2
- 240000002234 Allium sativum Species 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 2
- 240000006891 Artemisia vulgaris Species 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 2
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 2
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 2
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- 244000131522 Citrus pyriformis Species 0.000 claims description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 2
- 240000004784 Cymbopogon citratus Species 0.000 claims description 2
- 235000017897 Cymbopogon citratus Nutrition 0.000 claims description 2
- 244000133098 Echinacea angustifolia Species 0.000 claims description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 2
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 2
- 229920002079 Ellagic acid Polymers 0.000 claims description 2
- 244000004281 Eucalyptus maculata Species 0.000 claims description 2
- 241001071795 Gentiana Species 0.000 claims description 2
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 241000546188 Hypericum Species 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013740 Juglans nigra Nutrition 0.000 claims description 2
- 244000184861 Juglans nigra Species 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 244000178870 Lavandula angustifolia Species 0.000 claims description 2
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 2
- 240000003553 Leptospermum scoparium Species 0.000 claims description 2
- 102000004882 Lipase Human genes 0.000 claims description 2
- 108090001060 Lipase Proteins 0.000 claims description 2
- 239000004367 Lipase Substances 0.000 claims description 2
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 2
- 235000014749 Mentha crispa Nutrition 0.000 claims description 2
- 244000246386 Mentha pulegium Species 0.000 claims description 2
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 2
- 244000078639 Mentha spicata Species 0.000 claims description 2
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 2
- 235000008898 Morinda citrifolia Nutrition 0.000 claims description 2
- 240000004371 Panax ginseng Species 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims description 2
- BDIAUFOIMFAIPU-KVJIRVJXSA-N Valtratum Chemical compound C([C@]12[C@@H]3C(C(=CO[C@H]3OC(=O)CC(C)C)COC(C)=O)=C[C@@H]1OC(=O)CC(C)C)O2 BDIAUFOIMFAIPU-KVJIRVJXSA-N 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 229930013930 alkaloid Natural products 0.000 claims description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 2
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000010081 allicin Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 230000000843 anti-fungal effect Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 229960001948 caffeine Drugs 0.000 claims description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
- 230000009084 cardiovascular function Effects 0.000 claims description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 2
- 230000001149 cognitive effect Effects 0.000 claims description 2
- 229920002770 condensed tannin Polymers 0.000 claims description 2
- 102000038379 digestive enzymes Human genes 0.000 claims description 2
- 108091007734 digestive enzymes Proteins 0.000 claims description 2
- 235000014134 echinacea Nutrition 0.000 claims description 2
- 235000004132 ellagic acid Nutrition 0.000 claims description 2
- 229960002852 ellagic acid Drugs 0.000 claims description 2
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 2
- 235000004611 garlic Nutrition 0.000 claims description 2
- 229940068052 ginkgo biloba extract Drugs 0.000 claims description 2
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims description 2
- 229930184727 ginkgolide Natural products 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 229940107702 grapefruit seed extract Drugs 0.000 claims description 2
- 235000009569 green tea Nutrition 0.000 claims description 2
- 235000001050 hortel pimenta Nutrition 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 239000001102 lavandula vera Substances 0.000 claims description 2
- 235000018219 lavender Nutrition 0.000 claims description 2
- 229930013686 lignan Natural products 0.000 claims description 2
- 235000009408 lignans Nutrition 0.000 claims description 2
- 235000019421 lipase Nutrition 0.000 claims description 2
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 2
- 229940052404 nasal powder Drugs 0.000 claims description 2
- 239000001711 nigella sativa Substances 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 235000018192 pine bark supplement Nutrition 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 claims description 2
- 235000018291 probiotics Nutrition 0.000 claims description 2
- 229940106796 pycnogenol Drugs 0.000 claims description 2
- 235000005875 quercetin Nutrition 0.000 claims description 2
- 229930004725 sesquiterpene Natural products 0.000 claims description 2
- 150000004354 sesquiterpene derivatives Chemical class 0.000 claims description 2
- 238000012384 transportation and delivery Methods 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 229940068146 valepotriate Drugs 0.000 claims description 2
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims description 2
- 235000020767 valerian extract Nutrition 0.000 claims description 2
- 229940005605 valeric acid Drugs 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 244000141009 Hypericum perforatum Species 0.000 claims 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 241000411851 herbal medicine Species 0.000 claims 1
- 239000002085 irritant Substances 0.000 claims 1
- 231100000021 irritant Toxicity 0.000 claims 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims 1
- 229960001285 quercetin Drugs 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 abstract description 29
- 239000000499 gel Substances 0.000 abstract description 13
- 210000003928 nasal cavity Anatomy 0.000 abstract description 4
- 229920002678 cellulose Polymers 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 239000000321 herbal drug Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 230000000420 mucociliary effect Effects 0.000 description 11
- 210000001331 nose Anatomy 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000012678 infectious agent Substances 0.000 description 8
- 210000002850 nasal mucosa Anatomy 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 206010039085 Rhinitis allergic Diseases 0.000 description 7
- 201000010105 allergic rhinitis Diseases 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 230000001632 homeopathic effect Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 201000009961 allergic asthma Diseases 0.000 description 3
- 230000001886 ciliary effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 241000700605 Viruses Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 2
- 230000004800 psychological effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010051841 Exposure to allergen Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241001397173 Kali <angiosperm> Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Abstract
Description
関連する分析証明書(Certificate of Analysis)を用いて、全ての物質を確認した。成分を個別に検量した。ついで、リボンブレンダー又は類似タイプのブレンダーを用いて、成分を20分間混合した。ついで、使用前に、ブレンドした粉末を密閉容器中に分注(dispense)した。
関連する分析証明書を用いて、全ての物質を確認した。成分を個別に検量した。ついで、リボンブレンダー又は類似タイプのブレンダーを用いて、成分を20分間混合した。ついで、使用前に、ブレンドした粉末を密閉容器中に分注した。
関連する分析証明書を用いて、全ての物質を確認した。成分を個別に検量した。ついで、リボンブレンダー又は類似タイプのブレンダーを用いて、成分を20分間混合した。ついで、使用前に、ブレンドした粉末を密閉容器中に分注した。
Claims (14)
- およそ10〜20 Pa.sの粘度を有するヒドロキシプロピルメチルセルロースと、1種以上の治療剤とを含む、経鼻用乾燥粉末組成物。
- 前記ヒドロキシプロピルメチルセルロースの粘度が、およそ13〜17 Pa.s、より好ましくはおよそ14〜16 Pa.s、最も好ましくはおよそ15 Pa.sである、請求項1記載の乾燥粉末組成物。
- 前記治療剤が、経鼻投与時に全身的な効果を有する、請求項1又は2記載の乾燥粉末組成物。
- 前記組成物が、前記治療剤の持続的な放出を提供する、請求項1乃至3のいずれか一項記載の乾燥粉末組成物。
- 前記治療剤が、薬草の薬剤又はホメオパシー剤である、請求項1乃至4のいずれか一項記載の乾燥粉末組成物。
- 前記治療剤が、1つ以上の以下の特性:抗菌及び/又は抗真菌性、抗ウイルス性、抗生物質性、抗炎症性、抗不眠性、認識促進性、又は心臓血管機能に影響を及ぼす特性、を有する、請求項5記載の乾燥粉末組成物。
- 前記治療剤が、アスピリン、セントジョーンズワート、バレリアン抽出物(セスキテルペン、バレリアン酸、イリドイド、バレポトリエート、アルカロイド、フラノフランリグナン、アミノ酸、γ−アミノ酪酸、チロシン、アルギニン、グルタミン、又はこれらの任意の組み合わせが含まれてよい)、イチョウ葉エキス(フラボノイド、ギンコライド及びビロバライド、又はこれらの任意の組み合わせが含まれてよい)、ビタミンA、E、若しくはC、ニンニク、ライム、1種以上のプロバイオティクス、生姜、エラグ酸、エキナセア、スウェーデン花粉、ブラックウォールナットの外皮、レモングラス、ヨモギ、グレープフルーツ種子抽出物、ブロッコリー、消化酵素、ヒアルロン酸、ゲンゲ、ローズヒップ、リンドウ、オトギリソウ、トチノキ、朝鮮人参、緑茶、ホスファチジルセリン、ホスファチジルコリン、シトラス、ピクノジェノール、カフェイン、ケルセチン、コエンザイムQ10、ノコギリソウ、ティーツリー、ノニジュース(モリンダ・シトリフォリア)、リパーゼ、フルクト−オリゴ糖、イヌリン、ブラッククミン(ニゲラ・サティバ)、アリシン、又はこれらの任意の組み合わせである、請求項5又は6記載の乾燥粉末組成物。
- 前記粉末セルロースが、前記組成物の総重量の少なくとも50%、好ましくは少なくとも60、70、80、90、95、97、又は99%を構成する、請求項1乃至7のいずれか一項記載の乾燥粉末組成物。
- 前記治療的活性剤と粉末セルロースとの比が、2.5:7.5〜3.6:6.4である、請求項1乃至8のいずれか一項記載の乾燥粉末組成物。
- シグナル伝達物質をさらに含む、請求項1乃至9のいずれか一項記載の乾燥粉末組成物。
- 前記シグナル伝達物質が、メントール、ミント、スペアミント、ペパーミント、ユーカリ、ラベンダー、シトラス、レモン、ライム、又はこれらの任意の組み合わせである、請求項10記載の乾燥粉末組成物。
- 前記シグナル伝達物質が、前記組成物の総重量の最大で50%、好ましくは最大で40、30、20、10、5、2、1、0.5、又は0.25%を構成する、請求項10又は11記載の組成物。
- 刺激物又は他の添加物を実質的に含まない、請求項1乃至12のいずれか一項記載の組成物。
- 請求項1乃至13のいずれか一項記載の乾燥粉末組成物の鼻道へのデリバリーに適した、前記組成物を含むデバイス。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007535251A JP5254618B2 (ja) | 2004-10-11 | 2005-10-10 | 経鼻投与用組成物 |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0422582A GB0422582D0 (en) | 2004-10-11 | 2004-10-11 | Pharmaceutical compositions |
GB0422582.7 | 2004-10-11 | ||
GB0502792.5 | 2005-02-10 | ||
GB0502792A GB2419528A (en) | 2004-10-11 | 2005-02-10 | Cellulose powder and signalling agent composition suitable for nasal administration |
JP2005209097A JP2007022971A (ja) | 2005-07-19 | 2005-07-19 | 経鼻投与のための組成物 |
JP2005209097 | 2005-07-19 | ||
GB0519213.3 | 2005-09-21 | ||
GB0519213A GB2420707A (en) | 2004-10-11 | 2005-09-21 | Compositions for intranasal administration |
JP2007535251A JP5254618B2 (ja) | 2004-10-11 | 2005-10-10 | 経鼻投与用組成物 |
PCT/GB2005/050179 WO2006040596A2 (en) | 2004-10-11 | 2005-10-10 | Compositions for intranasal administration |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008515870A true JP2008515870A (ja) | 2008-05-15 |
JP5254618B2 JP5254618B2 (ja) | 2013-08-07 |
Family
ID=36010898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007535251A Active JP5254618B2 (ja) | 2004-10-11 | 2005-10-10 | 経鼻投与用組成物 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1824450B1 (ja) |
JP (1) | JP5254618B2 (ja) |
CA (1) | CA2583794C (ja) |
PL (1) | PL1824450T3 (ja) |
WO (1) | WO2006040596A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017527608A (ja) * | 2014-06-10 | 2017-09-21 | ナサリーズ パテンツ リミテッド | 経鼻組成物と該経鼻組成物の使用方法の改善 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110217394A1 (en) * | 2000-12-05 | 2011-09-08 | Brett Justin West | Iridoid Based Formulations |
US8790727B2 (en) * | 2000-12-05 | 2014-07-29 | Tahitian Noni International, Inc. | Morinda citrifolia and iridoid based formulations |
US9770047B2 (en) * | 2008-04-10 | 2017-09-26 | U.S. Nutraceuticals, LLC | Perilla seed composition |
US9610313B2 (en) | 2008-04-10 | 2017-04-04 | U.S. Nutraceuticals | Eye health composition and method using plant derived seed extract rich in essential fatty acids derived from perilla seed and carotenoids |
CA2923767A1 (en) | 2016-03-14 | 2017-09-14 | Timothy R. St. Germain | Method of using n-hydroxy-1,4-napthalenedione as a novel herbicide |
MX2019001313A (es) * | 2016-08-05 | 2019-09-26 | Shin Nippon Biomedical Laboratories Ltd | Composiciones farmaceuticas. |
US20180221426A1 (en) | 2017-02-06 | 2018-08-09 | William Van Dover Stoecker | Compositions and Methods for Treating and Removing Seborrheic Keratoses |
CN106821980B (zh) * | 2017-02-17 | 2019-10-18 | 成都博创必成生物技术有限公司 | 一种鼻腔喷雾剂及其制备方法和生物阻隔膜 |
CN106890197B (zh) * | 2017-04-11 | 2018-07-31 | 成都益植生物科技有限公司 | 一种定植益生菌制剂及其应用和药物 |
EP3960194B1 (de) * | 2020-09-01 | 2024-03-20 | Volker Loos | Zusammensetzung zur verminderung der symptome der nykturie |
GB202205769D0 (en) * | 2022-04-20 | 2022-06-01 | Nasaleze Patents Ltd | Compositions and applications therefor |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61194034A (ja) * | 1985-02-25 | 1986-08-28 | Teijin Ltd | 経鼻投与用粉末状組成物 |
WO1992016196A1 (en) * | 1991-03-20 | 1992-10-01 | Novo Nordisk A/S | A composition comprising a peptide for nasal administration |
WO1993025193A1 (en) * | 1992-06-12 | 1993-12-23 | Teijin Limited | Pharmaceutical preparation for intra-airway administration |
JPH0925238A (ja) * | 1995-07-12 | 1997-01-28 | L T T Kenkyusho:Kk | 経鼻投与用製剤 |
JPH09227373A (ja) * | 1996-02-21 | 1997-09-02 | Teijin Ltd | 抗インフルエンザウイルス剤 |
WO1997031626A1 (fr) * | 1996-02-27 | 1997-09-04 | Teijin Limited | Composition pulverulente destinee a une adminstration nasale |
WO2000002574A1 (fr) * | 1998-07-08 | 2000-01-20 | Kirin-Amgen Inc. | Preparation en poudre pour administration par les muqueuses |
JP2001131057A (ja) * | 1999-08-26 | 2001-05-15 | Takeda Chem Ind Ltd | 鼻粘膜付着マトリックス |
JP2004018491A (ja) * | 2002-06-19 | 2004-01-22 | Taisho Pharmaceut Co Ltd | プロスタグランジン含有経鼻投与製剤組成物 |
WO2004078211A1 (ja) * | 2003-03-04 | 2004-09-16 | Tanabe Seiyaku Co., Ltd. | 粉末経鼻投与製剤 |
-
2005
- 2005-10-10 JP JP2007535251A patent/JP5254618B2/ja active Active
- 2005-10-10 WO PCT/GB2005/050179 patent/WO2006040596A2/en active Application Filing
- 2005-10-10 CA CA2583794A patent/CA2583794C/en active Active
- 2005-10-10 PL PL05791723T patent/PL1824450T3/pl unknown
- 2005-10-10 EP EP05791723A patent/EP1824450B1/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61194034A (ja) * | 1985-02-25 | 1986-08-28 | Teijin Ltd | 経鼻投与用粉末状組成物 |
WO1992016196A1 (en) * | 1991-03-20 | 1992-10-01 | Novo Nordisk A/S | A composition comprising a peptide for nasal administration |
WO1993025193A1 (en) * | 1992-06-12 | 1993-12-23 | Teijin Limited | Pharmaceutical preparation for intra-airway administration |
JPH0925238A (ja) * | 1995-07-12 | 1997-01-28 | L T T Kenkyusho:Kk | 経鼻投与用製剤 |
JPH09227373A (ja) * | 1996-02-21 | 1997-09-02 | Teijin Ltd | 抗インフルエンザウイルス剤 |
WO1997031626A1 (fr) * | 1996-02-27 | 1997-09-04 | Teijin Limited | Composition pulverulente destinee a une adminstration nasale |
WO2000002574A1 (fr) * | 1998-07-08 | 2000-01-20 | Kirin-Amgen Inc. | Preparation en poudre pour administration par les muqueuses |
JP2001131057A (ja) * | 1999-08-26 | 2001-05-15 | Takeda Chem Ind Ltd | 鼻粘膜付着マトリックス |
JP2004018491A (ja) * | 2002-06-19 | 2004-01-22 | Taisho Pharmaceut Co Ltd | プロスタグランジン含有経鼻投与製剤組成物 |
WO2004078211A1 (ja) * | 2003-03-04 | 2004-09-16 | Tanabe Seiyaku Co., Ltd. | 粉末経鼻投与製剤 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017527608A (ja) * | 2014-06-10 | 2017-09-21 | ナサリーズ パテンツ リミテッド | 経鼻組成物と該経鼻組成物の使用方法の改善 |
Also Published As
Publication number | Publication date |
---|---|
PL1824450T3 (pl) | 2013-04-30 |
WO2006040596A2 (en) | 2006-04-20 |
JP5254618B2 (ja) | 2013-08-07 |
WO2006040596A3 (en) | 2006-06-01 |
CA2583794C (en) | 2015-05-26 |
EP1824450A2 (en) | 2007-08-29 |
CA2583794A1 (en) | 2006-04-20 |
EP1824450B1 (en) | 2012-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5254618B2 (ja) | 経鼻投与用組成物 | |
US11583519B2 (en) | Nasal compositions and method of use thereof | |
CA2726221C (en) | Antiallergic marine biopolymers | |
JP2022088592A (ja) | アルコール使用障害の処置のための組成物、装置、及び、方法 | |
AU2015289150B2 (en) | Orodispersible film | |
ES2601860T3 (es) | Comprimidos efervescentes para su uso por inhalación | |
US20200390691A1 (en) | Compositions, devices, and methods for the treatment of overdose and reward-based disorders | |
US8202550B2 (en) | Compositions for intranasal administration | |
GB2420707A (en) | Compositions for intranasal administration | |
WO2020132263A1 (en) | Compositions, devices, and methods for the treatment of overdose and reward-based disorders | |
KR101458670B1 (ko) | 분지쇄아미노산을 함유하는 약제학적 조성물 및 그 제조방법 | |
RU2781144C2 (ru) | Усовершенствование назальных композиций и способ их использования | |
JP2007022971A (ja) | 経鼻投与のための組成物 | |
JP2011251954A (ja) | 安全弁を有する経口フィルム製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080624 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080624 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080723 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081009 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090611 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090611 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090729 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120409 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121211 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130306 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130402 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130418 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5254618 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160426 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |